The diminished OCL formation following EAAT1 inhibition supports previous studies, which suggested a possible involvement of Glu signaling in the skeletal system [14, 19, 33], and the possible exploitation of Glu transport as a novel therapeutic target in MM-induced bone resorption. The gene discussed is SLC1A3; the disease is Miyoshi myopathy.